logo
  

Yum! Brands CEO David Gibbs Appointed To Under Armour Board - Quick Facts

Under Armour, Inc. (UA,UAA) announced Monday that David Gibbs, Chief Executive Officer (CEO) of Yum! Brands, Inc. (YUM), had been appointed to its Board of Directors effective September 1, 2021.

Gibbs, 58, leads the company's overarching strategies, structure, people development, and culture to drive global growth and sales and profitability for more than 51,000 KFC, Pizza Hut, Taco Bell and The Habit Burger Grill restaurants.

Gibbs has been CEO of Yum! Brands since January 2020 and has served as a member of its board of directors since November 2019. During his 32-year career with Yum! Brands, Gibbs has held a variety of leadership positions in its KFC, Pizza Hut and Taco Bell divisions.

Before his CEO appointment, Gibbs was Yum! Brands' president and chief operating officer with global operating leadership of the KFC, Pizza Hut and Taco Bell divisions as well as president and chief operating officer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT